Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
{{output}}
We assessed the safety, efficacy, maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of selinexor, a first in class oral selective inhibitor of nuclear export (100 mg once weekly [QW] or 60 mg twice weekly), in combination with daratumumab (... ...
